Photo: opmed.doximity.com
May 16, 2025, 08:32
Major Changes in the Treatment of Urothelial Cancer – Tres Uramigas
Tres Uramigas shared a post on X:
“Disitamab vedotin + toripalimab improved OS and PFS vs Gem + platinum in patients with advanced UCIM with HER2 overexpression (IHC 1+, 2+, 3+).
Major changes in the treatment of urothelial cancer.”
Martin Zapata Laguad, Medical Oncologist and Internal Medicine Physician at National Cancer Institute of Colombia, commented this post:
“Excellent results, the question is uncertain… will there be a role for those low or very low HER2 expressers in the use of EV pembrolizumab?”
More posts featuring Tres Uramigas.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 16, 2025, 08:32
May 16, 2025, 08:21
May 16, 2025, 08:12
May 16, 2025, 07:54
May 16, 2025, 07:50
May 16, 2025, 07:27
May 16, 2025, 07:27
May 16, 2025, 07:14